Literature DB >> 17881147

Histopathologic consideration of fiducial gold markers inserted for real-time tumor-tracking radiotherapy against lung cancer.

Mikado Imura1, Koichi Yamazaki, Kanako C Kubota, Tomoo Itoh, Rikiya Onimaru, Yasushi Cho, Yasuhiro Hida, Kichizo Kaga, Yuya Onodera, Shigeaki Ogura, Hirotoshi Dosaka-Akita, Hiroki Shirato, Masaharu Nishimura.   

Abstract

PURPOSE: Internal fiducial gold markers, safely inserted with bronchoscopy, have been used in real-time tumor-tracking radiotherapy for lung cancer. We investigated the histopathologic findings at several points after the insertion of the gold markers. METHODS AND MATERIALS: Sixteen gold markers were inserted for preoperative marking in 7 patients who subsequently underwent partial resection of tumors by video-assisted thoracoscopic surgery within 7 days.
RESULTS: Fibrotic changes and hyperplasia of type 2 pneumocytes around the markers were seen 5 or 7 days after insertion, and fibrin exudation without fibrosis was detected 1 or 2 days after insertion.
CONCLUSIONS: Because fibroblastic changes start approximately 5 days after gold marker insertion, real-time tumor-tracking radiotherapy should be started >5 days after gold marker insertion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17881147     DOI: 10.1016/j.ijrobp.2007.06.064

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

Review 1.  Treatment of metastatic liver tumors using stereotactic ablative radiotherapy.

Authors:  Vimoj J Nair; Jason R Pantarotto
Journal:  World J Radiol       Date:  2014-02-28

Review 2.  Particle therapy of moving targets-the strategies for tumour motion monitoring and moving targets irradiation.

Authors:  Tomasz Kubiak
Journal:  Br J Radiol       Date:  2016-07-19       Impact factor: 3.039

3.  Feasibility, detectability and clinical experience with platinum fiducial seeds for MRI/CT fusion and real-time tumor tracking during CyberKnife® stereotactic ablative radiotherapy.

Authors:  Vimoj J Nair; Janos Szanto; Eric Vandervoort; Elizabeth Henderson; Leonard Avruch; Shawn Malone; Pantarotto Jason R
Journal:  J Radiosurg SBRT       Date:  2015

4.  Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.

Authors:  Norio Katoh; Itaru Soda; Hiroyasu Tamamura; Shotaro Takahashi; Yusuke Uchinami; Hiromichi Ishiyama; Kiyotaka Ota; Tetsuya Inoue; Rikiya Onimaru; Keiko Shibuya; Kazushige Hayakawa; Hiroki Shirato
Journal:  Radiat Oncol       Date:  2017-01-05       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.